Question 3 - SIU Kidney Cancer Quiz

Exit

Are you sure you want to exit the quiz? What about Prince Renaldo???

No, I want to continue

Yes, I want to exit

Level: Moderate

QUESTION 1:
Which of the following small molecule inhibitors is matched correctly with its target(s)?

a) Everolimus – PDGFR b) Lenvatinib – mTOR c) Tivozanib – FGFR, VEGFRs d) Cabozantinib – MET, Axl, VEGFRs e) Belzutifan – HIF1b

Correct

Incorrect, the correct answer is d

Submit

Level: Moderate

QUESTION 2:
Which patient subset had the highest benefit in disease-free survival (DFS) from KEYNOTE-564 of adjuvant pembrolizumab versus placebo?

a) T3/T4 N0 M0, any grade b) Tx N+ M0 c) M1 NED d) T2 N0 M0, grade 4 or sarcomatoid e) None of these options

Correct

Incorrect, the correct answer is c

Submit

Level: Moderate

QUESTION 3:
For immunotherapy refractory metastatic clear cell renal cell carcinoma, which of the following remains the preferred treatment based on randomized phase 3 data?

a) Cabozantinib b) Cabozantinib-atezolizumab c) Axitinib-pembrolizumab d) Lenvatinib-pembrolizumab e) Cabozantinib-nivolumab

Correct

Incorrect, the correct answer is a

Submit

Level: Moderate

QUESTION 4:
A patient with metastatic renal cell carcinoma is being treated with axitinib and pembrolizumab. He calls with new onset diarrhea 5-6 times over the past 24h. What is the usual first step in management?

a) Start loperamide b) Start IV solumedrol 1mg/kg c) Start oral prednisone 1mg/kg d) Start diphenoxylate and atropine e) Stop axitinib

Correct

Incorrect, the correct answer is e

Submit

Level: Moderate

QUESTION 5:
Which of the following is the preferred first-line treatment for metastatic papillary renal cell carcinoma?

a) Lenvatinib with pembrolizumab b) Cabozantinib with atezolizumab c) Cabozantinib d) Sunitinib e) Lenvatinib with everolimus

Correct

Incorrect, the correct answer is c

Submit

My humours are imbalanced? What’s that supposed to mean?

Continue

Level: Moderate

QUESTION 1:Which of the following small molecule inhibitors is matched correctly with its target(s)?

Level: Moderate

QUESTION 2:Which patient subset had the highest benefit in disease-free survival (DFS) from KEYNOTE-564 of adjuvant pembrolizumab versus placebo?

Level: Moderate

QUESTION 3:For immunotherapy refractory metastatic clear cell renal cell carcinoma, which of the following remains the preferred treatment based on randomized phase 3 data?

Level: Moderate

QUESTION 4:A patient with metastatic renal cell carcinoma is being treated with axitinib and pembrolizumab. He calls with new onset diarrhea 5-6 times over the past 24h. What is the usual first step in management?

Level: Moderate

QUESTION 5:Which of the following is the preferred first-line treatment for metastatic papillary renal cell carcinoma?

QUESTION 1:
Which of the following small molecule inhibitors is matched correctly with its target(s)?

QUESTION 2:
Which patient subset had the highest benefit in disease-free survival (DFS) from KEYNOTE-564 of adjuvant pembrolizumab versus placebo?

QUESTION 3:
For immunotherapy refractory metastatic clear cell renal cell carcinoma, which of the following remains the preferred treatment based on randomized phase 3 data?

QUESTION 4:
A patient with metastatic renal cell carcinoma is being treated with axitinib and pembrolizumab. He calls with new onset diarrhea 5-6 times over the past 24h. What is the usual first step in management?

QUESTION 5:
Which of the following is the preferred first-line treatment for metastatic papillary renal cell carcinoma?